Wall Street analysts expect ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) to post earnings of $0.99 per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for ANI Pharmaceuticals’ earnings. The highest EPS estimate is $1.00 and the lowest is $0.98. ANI Pharmaceuticals posted earnings per share of $1.09 in the same quarter last year, which would indicate a negative year-over-year growth rate of 9.2%. The company is scheduled to announce its next quarterly earnings results on Thursday, November 2nd.

On average, analysts expect that ANI Pharmaceuticals will report full year earnings of $3.87 per share for the current year, with EPS estimates ranging from $3.86 to $3.88. For the next fiscal year, analysts anticipate that the business will report earnings of $4.56 per share, with EPS estimates ranging from $4.40 to $4.71. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that cover ANI Pharmaceuticals.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.19. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. The business had revenue of $44.80 million for the quarter, compared to analyst estimates of $43.20 million. During the same period in the previous year, the business posted $1.11 earnings per share. The business’s revenue was up 43.0% compared to the same quarter last year.

Several analysts recently weighed in on the stock. Canaccord Genuity reiterated a “buy” rating and issued a $66.00 price objective (up from $60.00) on shares of ANI Pharmaceuticals in a research report on Monday, October 16th. BidaskClub upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Finally, Guggenheim reiterated a “buy” rating and issued a $80.00 price objective on shares of ANI Pharmaceuticals in a research report on Tuesday, July 4th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. ANI Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $67.33.

TRADEMARK VIOLATION WARNING: “Brokerages Anticipate ANI Pharmaceuticals, Inc. (ANIP) to Post $0.99 Earnings Per Share” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/22/brokerages-anticipate-ani-pharmaceuticals-inc-anip-to-post-0-99-earnings-per-share.html.

Institutional investors have recently added to or reduced their stakes in the business. Intrust Bank NA increased its stake in ANI Pharmaceuticals by 11.8% during the 2nd quarter. Intrust Bank NA now owns 5,051 shares of the specialty pharmaceutical company’s stock valued at $236,000 after buying an additional 535 shares during the period. Renaissance Technologies LLC increased its stake in ANI Pharmaceuticals by 7.0% during the 2nd quarter. Renaissance Technologies LLC now owns 297,400 shares of the specialty pharmaceutical company’s stock valued at $13,918,000 after buying an additional 19,400 shares during the period. Tudor Investment Corp ET AL increased its stake in ANI Pharmaceuticals by 80.4% during the 1st quarter. Tudor Investment Corp ET AL now owns 8,300 shares of the specialty pharmaceutical company’s stock valued at $411,000 after buying an additional 3,700 shares during the period. Kennedy Capital Management Inc. acquired a new position in ANI Pharmaceuticals during the 1st quarter valued at about $4,069,000. Finally, Ativo Capital Management LLC increased its stake in ANI Pharmaceuticals by 64.5% during the 2nd quarter. Ativo Capital Management LLC now owns 26,005 shares of the specialty pharmaceutical company’s stock valued at $1,217,000 after buying an additional 10,200 shares during the period. 55.81% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ANI Pharmaceuticals (ANIP) traded up 0.12% on Friday, hitting $59.09. 56,727 shares of the stock were exchanged. ANI Pharmaceuticals has a one year low of $42.23 and a one year high of $67.40. The firm has a market cap of $687.69 million, a price-to-earnings ratio of 129.30 and a beta of 3.05. The firm’s 50 day moving average price is $52.63 and its 200 day moving average price is $48.79.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get a free copy of the Zacks research report on ANI Pharmaceuticals (ANIP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.